Allogeneic Engineered NK Cell Therapy Development involves modifying natural killer (NK) cells from healthy donors to enhance their cancer-targeting capabilities. This off-the-shelf approach offers a scalable and cost-effective alternative to personalized therapies, reducing treatment timelines. Engineered NK cells are designed to improve specificity, persistence, and safety, making them a promising option for advancing cancer immunotherapy.